For patients diagnosed with HER2-low breast cancer, understanding your eligibility for trastuzumab deruxtecan (T-DXd) can be the difference between limited treatment options and access to a potentially transformative therapy. HER2-low breast cancer represents a newly recognized category where tumors express low levels of HER2 protein—historically misclassified as HER2-negative—and now qualifies for targeted treatment with this innovative antibody-drug conjugate. According to a 2022 analysis published in the New England Journal of Medicine, approximately 60% of tumors previously classified as HER2-negative actually fall into the HER2-low category when assessed with contemporary testing protocols, opening new pathways for thousands of patients worldwide.
This comprehensive guide walks you through everything you need to know about HER2-low trastuzumab deruxtecan eligibility criteria, including HER2 testing interpretation, clinical qualification requirements, cardiac and pulmonary monitoring protocols, and practical steps to work with your oncology team. You'll discover how your genetic test results determine treatment eligibility, what prior treatments you need to have received, and how to gather the medical documentation necessary for your eligibility assessment. Understanding these criteria empowers you to advocate for yourself and explore this potentially life-extending treatment option.
Understanding HER2-Low Breast Cancer and T-DXd Eligibility
HER2-low breast cancer qualifies patients for trastuzumab deruxtecan (T-DXd) when tumors show IHC 1+ expression or IHC 2+ with negative in situ hybridization (ISH) results. Eligibility also requires unresectable or metastatic disease with at least one prior chemotherapy line for metastatic setting, or disease recurrence within 6 months of adjuvant chemotherapy. For hormone receptor-positive disease, prior endocrine therapy is mandatory before T-DXd consideration. This classification emerged from landmark clinical trials demonstrating T-DXd's remarkable effectiveness in a patient population previously considered ineligible for HER2-targeted therapies.
What is HER2-Low Breast Cancer?
HER2-low breast cancer is defined as tumors with IHC 1+ or IHC 2+ paired with negative ISH results, representing a distinct biological category between HER2-negative (IHC 0) and HER2-positive (IHC 3+ or ISH-positive) disease. This classification emerged from clinical observations that a substantial percentage of HER2-negative tumors, when more carefully characterized, actually express modest amounts of HER2 protein. The biological significance became apparent when researchers noted that tumors with this intermediate HER2 expression responded to T-DXd despite being considered HER2-negative by traditional diagnostic criteria. The reclassification required updating pathology reporting standards and retraining pathologists in HER2-low detection, fundamentally changing how oncologists approach diagnosis and treatment planning for breast cancer patients.
How Trastuzumab Deruxtecan Works
Trastuzumab deruxtecan is an antibody-drug conjugate (ADC) that represents a sophisticated approach to targeted cancer therapy. The medication combines trastuzumab (a HER2-targeting antibody) with deruxtecan (a potent topoisomerase I inhibitor chemotherapy agent), creating a highly targeted delivery system. When T-DXd circulates through the bloodstream, the trastuzumab component binds to HER2 protein on cancer cell surfaces, and the complex is internalized into cells. Once inside, deruxtecan is released and inhibits topoisomerase I, an enzyme essential for DNA replication, leading to cancer cell death. The innovation of T-DXd lies in its efficacy at lower HER2 expression levels—unlike traditional HER2-targeted therapies requiring high HER2 expression (IHC 3+ or ISH-positive), T-DXd demonstrates clinical benefit even when HER2 is only modestly expressed, explaining its effectiveness in HER2-low disease.
Clinical Trial Evidence: DESTINY-Breast04 and DESTINY-Breast06
The DESTINY-Breast04 trial established the evidence foundation for T-DXd in HER2-low breast cancer, enrolling 336 patients with unresectable or metastatic HER2-low disease who had received at least one prior chemotherapy line. According to research published in the New England Journal of Medicine in 2022, T-DXd demonstrated a progression-free survival of 10.1 months compared to 5.4 months with chemotherapy alone, representing an 85% improvement in disease control. Objective response rates reached 62% with T-DXd versus 34% with chemotherapy, demonstrating not only longer survival without progression but also superior tumor shrinkage rates. The trial particularly benefited hormone receptor-positive patients, in whom T-DXd showed even greater efficacy, with median progression-free survival extending beyond 12 months in this subgroup.
The newer DESTINY-Breast06 trial, with 2025 data now available, expanded T-DXd's evidence base to chemotherapy-naive patients with HR-positive metastatic HER2-low breast cancer. This trial enrolled patients who had received prior endocrine therapy but no chemotherapy, establishing that T-DXd can be moved earlier in the treatment sequence for this population. The chemotherapy-naive eligibility criteria represent a significant advancement, offering patients the potential for better quality of life by potentially avoiding traditional chemotherapy. Both DESTINY-Breast04 and DESTINY-Breast06 data form the regulatory and clinical foundation for T-DXd eligibility determinations used by oncologists today.
HER2 Expression Testing and Classification
IHC (Immunohistochemistry) Scoring System
Immunohistochemistry (IHC) scoring forms the foundation of HER2 determination and T-DXd eligibility assessment. The IHC test uses antibodies against the HER2 protein to visualize and quantify HER2 expression in cancer cells viewed under microscopy. Pathologists score IHC results from 0 to 3+, with each score reflecting the percentage of cells showing membrane staining and the staining intensity. IHC 0 indicates no detectable HER2 expression (negative), IHC 1+ shows faint, incomplete membrane staining in more than 10% of cells (HER2-low), IHC 2+ displays moderate, complete membrane staining in more than 10% of cells (intermediate—may be HER2-low if ISH-negative), and IHC 3+ demonstrates strong, complete membrane staining (HER2-positive). For HER2-low eligibility, patients need either IHC 1+ regardless of ISH results, or IHC 2+ combined with negative ISH results.
The technical quality of IHC testing significantly impacts accuracy and T-DXd eligibility determinations. The College of American Pathologists (CAP) and American Society of Clinical Oncology (ASCO) updated HER2 testing guidelines in 2023 to specifically address HER2-low classification, emphasizing the importance of validated antibody clones (particularly 4B5 and SP3), proper tissue fixation lasting 6-72 hours, and experienced pathologist interpretation. Inter-observer concordance for IHC scoring ranges from 73-95%, with greatest variability occurring when distinguishing IHC 0 from IHC 1+ or IHC 2+ from IHC 3+. Many institutions have implemented quality assurance programs requiring pathologist training in HER2-low detection and periodic review of challenging cases. Patients should request detailed pathology reports specifying their exact IHC score rather than accepting vague terminology like "HER2-negative," which may actually encompass HER2-low tumors qualifying for T-DXd.
ISH (In Situ Hybridization) and Reflex Testing
In situ hybridization (ISH) testing measures HER2 gene amplification using DNA probes that directly detect HER2 gene copies within cancer cells. The most common ISH methodology is fluorescence in situ hybridization (FISH), which uses fluorescently labeled probes for HER2 and the reference gene CEP17, allowing pathologists to determine the HER2/CEP17 ratio. For HER2-low classification with IHC 2+ results, negative ISH criteria require HER2/CEP17 ratio less than 2.0 or fewer than 4 HER2 gene copies per cell. Other ISH techniques including chromogenic ISH (CISH) and multiplex ISH provide alternative methodologies achieving similar diagnostic accuracy. Reflex ISH testing—automatically performing ISH on all IHC 2+ cases—has become standard practice at many institutions following the 2023 CAP/ASCO guideline update, ensuring definitive HER2-low classification rather than ambiguous intermediate results.
Tumor heterogeneity complicates HER2 assessment, as HER2 expression may vary significantly within the same tumor or differ between the primary tumor and metastatic sites. Discordance rates of 10-20% between primary and metastatic HER2 status have been documented, emphasizing the importance of testing the most recent available tissue sample for accurate T-DXd eligibility determination. Current guidelines recommend HER2 testing on metastatic biopsy samples when available, as HER2-low status may emerge after metastatic progression even when the primary tumor was classified differently. Quality assurance protocols ensure test results meet standardized thresholds for HER2 gene copy numbers and ratios, preventing misclassification that could exclude eligible patients from T-DXd.
HER2-Ultralow: The NEW 2025 FDA Category
A significant development in 2025 involves FDA approval expansion of T-DXd to include HER2-ultralow patients—those with IHC 0 score showing minimal membrane staining. Historically, IHC 0 patients (truly HER2-negative) were excluded from T-DXd eligibility, but emerging clinical trial data from DESTINY-Breast05 and confirmatory data from DESTINY-Breast06 demonstrated clinical benefit even in this lower expression population. HER2-ultralow classification applies specifically to IHC 0 cases with detectable but minimal HER2 membrane expression, typically defined as staining intensity just above the threshold for complete negativity. This new category potentially expands the eligible patient population by several thousand additional breast cancer patients who were previously considered unsuitable for HER2-targeted approaches.
The ultralow designation reflects evolving understanding of HER2 biology and T-DXd's mechanism of action. Research indicates that even minimal HER2 expression provides sufficient target for the antibody-drug conjugate to bind and deliver cytotoxic payload, explaining clinical responses in ultralow patients. However, HER2-ultralow eligibility remains distinct from true HER2-negative (IHC 0 with no membrane staining), and pathologists must carefully characterize the distinction to accurately determine eligibility. Ask My DNA users interested in understanding their precise HER2 expression status and potential eligibility can access detailed genomic interpretation that complements traditional pathology reporting, providing comprehensive molecular context for treatment decision-making.
HER2-Low vs HER2-Negative vs HER2-Positive: Key Distinctions
Historical Misclassification Issues
For decades, HER2-low breast cancers were grouped with HER2-negative tumors, a classification error that prevented patients from accessing HER2-targeted therapies. Traditional HER2-positive/negative dichotomy categorized any tumor without strong HER2 expression as negative, lumping together both truly HER2-negative (IHC 0) and HER2-low (IHC 1+ or IHC 2+/ISH-negative) populations. This oversimplification reflected historical limitations in testing technology and understanding of HER2 biology. The 2023 CAP/ASCO guideline update formally recognized HER2-low as a distinct diagnostic category, requiring pathology reports to explicitly document this classification. Many patients diagnosed before 2023 may have archival tumor tissue previously reported only as "HER2-negative" without granular IHC scoring, potentially obscuring HER2-low status and excluding them from T-DXd eligibility.
Re-reviewing archival pathology has become increasingly important as HER2-low recognition spreads. Patients diagnosed 3-5 years ago with tumors reported as simply "HER2-negative" should discuss with their oncologist whether pathology re-review or repeat biopsy with contemporary testing is appropriate. Modern testing using validated antibody clones and experienced pathologists performing HER2-low-specific assessment can accurately identify HER2-low status in tissue originally reported as negative. This reclassification has profound implications—a patient previously thought to be HER2-negative and therefore unsuitable for HER2-targeted therapy may actually be HER2-low and qualify for potentially more effective T-DXd treatment.
Clinical Implications for Treatment Selection
The distinction between HER2-positive, HER2-low, and HER2-negative carries dramatic implications for optimal treatment selection. HER2-positive patients (IHC 3+ or ISH-positive) receive trastuzumab and pertuzumab as cornerstones of treatment, along with various chemotherapy combinations and newer agents, representing a highly established and effective treatment paradigm. HER2-negative patients historically received standard chemotherapy without HER2-targeted components, as no effective HER2-targeted therapy existed for this population. HER2-low patients now occupy a newly defined middle ground, representing an estimated 50-70% of previously classified HER2-negative tumors, with access to T-DXd therapy that demonstrates superior efficacy compared to standard chemotherapy alone. This distinction fundamentally changes treatment planning discussions—a patient initially counseled that no HER2-targeted option existed may now be eligible for precision medicine approaching similar to HER2-positive disease.
Treatment sequencing also depends critically on accurate HER2 classification. HER2-positive disease benefits from earlier introduction of HER2-targeted therapy, even in early-stage settings. HER2-low disease with T-DXd shows benefit primarily in advanced/metastatic settings based on current trial data, though earlier-stage trials are ongoing. HER2-negative disease remains limited to conventional chemotherapy, endocrine therapy for HR-positive cases, and immunotherapy in specific contexts. Misclassification in either direction—treating HER2-low as negative and missing T-DXd opportunity, or treating HER2-negative as HER2-low and using ineffective therapy—results in suboptimal outcomes. Accurate HER2 determination through contemporary testing protocols therefore directly impacts survival and quality of life for breast cancer patients.
T-DXd Eligibility Criteria: Complete Assessment
HER2 Testing Requirements
T-DXd eligibility requires confirmation of HER2-low status through contemporary testing meeting CAP/ASCO 2023 standards. The standard eligibility criteria include IHC 1+ regardless of ISH results, or IHC 2+ combined with negative ISH (HER2/CEP17 ratio <2.0 or <4 HER2 copies per cell). The newly approved HER2-ultralow category (2025+) adds IHC 0 with minimal detectable membrane expression as eligible, expanding the patient population. Pathology reports should explicitly document the IHC score, ISH methodology, HER2/CEP17 ratio or HER2 copy number values, and pathologist interpretation regarding HER2-low status—not merely "positive" or "negative" terminology that obscures critical details. Patients should verify these specifics are documented in their pathology reports and understand their exact HER2 classification before consulting with oncologists about T-DXd eligibility.
Testing methodology quality directly impacts eligibility determinations and treatment outcomes. The CAP and ASCO guidelines emphasize validated HER2 antibody clones (4B5 and SP3 showing highest concordance with fluorescence in situ hybridization), proper tissue fixation time of 6-72 hours, and experienced pathologist interpretation specifically trained in HER2-low detection. Laboratories participating in CAP proficiency testing demonstrate higher accuracy in HER2 determination compared to laboratories without external quality validation. If historical pathology reports lack explicit IHC scores or ISH results, patients should discuss with their oncologist whether pathology re-review by an experienced pathologist or repeat biopsy with contemporary testing is warranted. This is particularly important if the original testing was performed more than 2-3 years ago, before widespread adoption of HER2-low classification protocols.
Disease Status Requirements
T-DXd eligibility requires unresectable locally advanced or metastatic disease—not early-stage disease suitable for surgery or radiation. Unresectable disease means tumors that cannot be completely removed by surgical techniques due to location, extent, or patient factors, requiring systemic therapy as primary treatment. Metastatic disease extends beyond the breast and regional lymph nodes to distant organs such as bones, lungs, liver, or brain, representing incurable disease where treatment aims to extend survival and manage symptoms. Early-stage breast cancer, even if HER2-low, does not qualify for T-DXd based on current evidence, as DESTINY trials enrolled only advanced disease populations and early-stage benefit remains unproven. Imaging documentation establishing unresectable or metastatic status—through computed tomography, positron emission tomography, or other modalities—forms a critical component of T-DXd eligibility verification.
The distinction between locally advanced unresectable and metastatic disease carries clinical importance for treatment planning and prognosis. Locally advanced unresectable disease confined to the breast and regional lymph nodes may potentially be rendered resectable after systemic therapy and subsequent surgery, while metastatic disease represents systemic cancer requiring lifelong disease management. However, both locally advanced unresectable and metastatic statuses qualify for T-DXd, as the fundamental requirement is absence of complete surgical resectability and the need for systemic chemotherapy. Patients should clearly understand their disease stage and staging imaging with their oncology team to confirm eligibility status.
Prior Treatment Requirements: Chemotherapy and Endocrine
For previously treated patients (DESTINY-Breast04 population), T-DXd eligibility requires at least one prior chemotherapy line in the metastatic setting, or disease recurrence within 6 months of completing adjuvant chemotherapy. "Prior chemotherapy line" refers to a complete chemotherapy regimen (such as paclitaxel monotherapy, docetaxel monotherapy, anthracycline-based regimens, or platinum-containing combinations) administered for metastatic disease, or adjuvant chemotherapy completed at least 12 months before metastatic recurrence. The 6-month recurrence criterion within adjuvant completion is important—if disease recurs between 6-12 months after adjuvant chemotherapy, that counts as meeting the "prior chemotherapy" requirement even without additional metastatic chemotherapy. For hormone receptor-positive disease, prior endocrine therapy is also required, including at least one line of hormone therapy such as CDK4/6 inhibitors, aromatase inhibitors, tamoxifen, or fulvestrant.
The chemotherapy-naive pathway (DESTINY-Breast06) offers a newer eligibility route for selected patients. This pathway applies only to hormone receptor-positive, metastatic HER2-low breast cancer without any prior chemotherapy. These patients must have received prior endocrine therapy (at least one line, typically CDK4/6 inhibitor with aromatase inhibitor, or single-agent hormone therapy) but no chemotherapy. This represents a significant advancement allowing T-DXd as first-line chemotherapy for appropriately selected HR-positive patients, potentially improving quality of life by deferring standard chemotherapy toxicity. However, chemotherapy-naive eligibility does not apply to hormone receptor-negative HER2-low patients, who must still have received at least one prior chemotherapy line.
Cardiac and Pulmonary Function Baseline
T-DXd carries risk of left ventricular ejection fraction (LVEF) decline and interstitial lung disease (ILD), requiring careful baseline assessment before treatment initiation. Baseline LVEF determination through echocardiography or MUGA scan is mandatory before starting T-DXd, establishing a reference point for monitoring during treatment. Normal LVEF typically exceeds 50%, though specific institutional lower limits of normal vary. Patients with baseline LVEF below institutional lower limits may not be suitable candidates for T-DXd, or may require more intensive cardiac monitoring protocols. Baseline pulmonary assessment includes chest radiography or computed tomography to establish normal baseline imaging and assess for pre-existing interstitial abnormalities that might increase ILD risk. Pulmonary function testing may be considered for patients with baseline risk factors for ILD, such as prior chest radiation or pre-existing pulmonary disease.
The cardiac and pulmonary baseline assessment represents essential infrastructure for safe T-DXd administration. These baseline measurements allow oncology teams to detect subtle changes during treatment, distinguishing treatment-related toxicity from pre-existing conditions or disease progression. Patients should explicitly discuss baseline cardiac and pulmonary assessment timing with their oncology team, understanding that T-DXd initiation will not proceed until these assessments are complete and results reviewed.
Understanding which specific T-DXd eligibility pathway applies to your situation—whether you're previously treated with ≥1 chemotherapy line or chemotherapy-naive HR-positive requiring prior endocrine therapy—directly shapes your treatment planning and potential benefit timeline. If you're uncertain about your eligibility status or want to explore how your individual genetic profile might influence your response to T-DXd and supportive treatments, Ask My DNA provides detailed pharmacogenomic analysis of how variants in genes like CYP3A4 and other drug metabolizers affect treatment tolerability and effectiveness.
Step-by-Step Eligibility Assessment Protocol
Gathering Your Medical Records
Begin your T-DXd eligibility assessment by obtaining complete, detailed pathology reports from all breast cancer biopsies—primary diagnosis and any subsequent metastatic biopsies. Request specific IHC score documentation (0, 1+, 2+, or 3+) rather than accepting vague "positive" or "negative" terminology that might obscure HER2-low status. For any IHC 2+ results, verify that ISH testing was performed with specific HER2/CEP17 ratio and HER2 copy number values clearly documented. If pathology reports lack these specifics or were generated before 2023, request pathology re-review or consider repeat biopsy of accessible metastatic disease with contemporary HER2 testing protocols meeting CAP/ASCO 2023 standards.
Simultaneously, compile your complete treatment history including dates, drug names, and doses of all prior chemotherapy regimens, endocrine therapies (for HR-positive disease), targeted therapies, and immunotherapy. Document whether chemotherapy was administered in adjuvant (post-surgical) or metastatic (advanced disease) settings, as this distinction affects T-DXd eligibility timing requirements. Gather all imaging studies demonstrating disease status—recent computed tomography or positron emission tomography scans showing unresectable or metastatic extent. Organize this documentation chronologically in a single folder that you can bring to oncology appointments, creating a comprehensive medical portfolio that facilitates your eligibility assessment discussion.
Understanding Your HER2 Test Results
Review your pathology reports carefully to identify your specific HER2 classification. If your report states IHC 1+, you meet HER2-low criteria and qualify for T-DXd regardless of ISH results. If your report states IHC 2+, look for ISH results—if ISH-negative (ratio <2.0 or <4 copies), you are HER2-low and T-DXd-eligible; if ISH-positive, you are HER2-positive and require traditional HER2-targeted therapy rather than T-DXd. If your report states only "HER2-negative" without specific IHC score documentation, particularly if testing occurred before 2023, this may indicate HER2-low disease that was misclassified and warrants pathology re-review or repeat biopsy. If your report states IHC 0, and if there is any mention of minimal membrane staining detected on modern testing, you may fall into the new HER2-ultralow category (approved 2025+) and qualify for T-DXd.
If you're uncertain about your HER2 classification or suspect misclassification, discuss with your medical oncologist whether your pathologist can provide more granular detail on the original pathology or whether contemporary re-testing is appropriate. Many comprehensive cancer centers can facilitate pathology review by HER2-expert pathologists if questions exist. Understanding your precise HER2 classification—not just "negative" or "positive" but specific IHC score and ISH status—is foundational to accurate T-DXd eligibility determination.
Consulting with Your Oncology Team
Schedule a dedicated consultation with your medical oncologist specifically focused on T-DXd eligibility assessment. Bring your organized medical documentation including pathology reports with explicit HER2 scores and ISH results, treatment timeline showing all prior chemotherapy and endocrine therapy with dates, and imaging demonstrating current disease status. Present this documentation clearly and ask your oncologist to explicitly confirm or deny your T-DXd eligibility based on HER2 expression level, disease status, prior treatment history, and cardiac/pulmonary function. If your oncologist indicates uncertainty about your HER2 classification, discuss whether pathology re-review by an expert pathologist or repeat biopsy with contemporary testing is warranted.
Ask your oncologist about baseline cardiac and pulmonary function assessment logistics—which tests will be performed, who orders them, and when results will be reviewed before potential T-DXd initiation. Discuss any cardiac risk factors (prior cardiotoxic chemotherapy, hypertension, diabetes) or pulmonary risk factors (prior chest radiation, smoking history, chronic lung disease) that might affect T-DXd tolerability. If your doctor raises concerns about eligibility or safety, ask about clinical trial alternatives potentially expanding T-DXd access to earlier treatment lines or special populations. Request referral to a comprehensive cancer center with extensive T-DXd experience if you desire a second opinion on eligibility or treatment sequencing.
Safety Monitoring and Adverse Effects
Cardiotoxicity: LVEF Monitoring Protocol
Trastuzumab deruxtecan carries risk of decreased left ventricular ejection fraction (LVEF), an important measure of heart function representing the percentage of blood the heart pumps with each contraction. Why LVEF monitoring is critical: HER2-targeted therapies like trastuzumab and T-DXd can injure heart muscle cells through their mechanism of action, potentially leading to cardiomyopathy (weakened heart function) in some patients. Baseline LVEF assessment through echocardiography or MUGA (multigated acquisition) scan documents starting cardiac function before treatment begins. Standard LVEF exceeds 50%, with specific institutional "lower limits of normal" typically ranging 45-50%. Monitoring schedule includes repeat LVEF assessment at 1 month after T-DXd initiation, then every 3 months during continued treatment.
Dose modification or discontinuation triggers occur if LVEF declines greater than 10 percentage points from baseline (for example, dropping from 55% to 45%) or falls below institutional lower limits of normal. Many patients experience grade 1 LVEF decline (mild decrease) without requiring dose modification. Grade 2 (symptomatic heart failure or >20% decline from baseline) typically requires dose reduction to 4.4 mg/kg or 3.2 mg/kg, or temporary treatment discontinuation pending cardiac recovery. Grade 3-4 (severe cardiomyopathy or LVEF <30%) usually necessitates permanent discontinuation. Patients with baseline LVEF below 50% or history of significant cardiotoxicity from prior chemotherapy should discuss cardiac risk-benefit with their oncology team before T-DXd initiation.
Interstitial Lung Disease (ILD): Most Serious Risk
Interstitial lung disease (ILD) represents the most serious potential T-DXd adverse effect, affecting approximately 12% of treated patients with 0.8% fatal outcomes in clinical trials. ILD is a group of conditions characterized by inflammation and scarring of lung tissue causing progressive breathing difficulty, typically manifesting as new or worsening cough, dyspnea (shortness of breath), fever, or chest discomfort. The mechanism involves T-DXd's deruxtecan component triggering pulmonary inflammation in susceptible patients, though predictive biomarkers for ILD susceptibility remain incompletely understood. Grade 1 ILD (asymptomatic radiologic findings) may allow continuation with close monitoring. Grade 2 or higher ILD (symptomatic or significant imaging changes) requires permanent treatment discontinuation, as continued T-DXd risks life-threatening ILD progression.
ILD surveillance protocols include baseline chest imaging (radiography or computed tomography) before treatment, establishing normal baseline for comparison. During treatment, any respiratory symptoms—new cough, increased dyspnea, fever—should prompt immediate evaluation with chest CT and pulmonary function tests, not waiting for scheduled visits. Treatment discontinuation for grade 2+ ILD is mandatory, though some case reports describe potential recovery of ILD symptoms after discontinuation, particularly if caught early. Patients should educate themselves on ILD symptoms and report any respiratory concerns immediately rather than attributing them to other causes. Baseline pulmonary function testing may be considered for patients with pre-existing lung disease or significant ILD risk factors.
Other Monitoring Parameters
Complete blood count (CBC) monitoring before each T-DXd infusion detects myelosuppression—neutropenia (low white blood cells), anemia (low red blood cells), or thrombocytopenia (low platelets)—requiring potential dose delays or reductions. Neutropenia grade 3-4 (absolute neutrophil count <500/mcL) typically triggers treatment delay pending recovery. Dose reductions to 4.4 mg/kg or 3.2 mg/kg (from standard 5.4 mg/kg) manage ongoing myelosuppression while attempting to preserve T-DXd benefit. Response assessment using RECIST (Response Evaluation Criteria in Solid Tumors) criteria requires imaging every 6-9 weeks to determine if tumors are shrinking, stable, or progressing, guiding ongoing treatment continuation or modifications.
Dosing schedule remains 5.4 mg/kg intravenous infusion every 3 weeks, with each infusion requiring pre-treatment blood work confirming adequate blood counts and renal/hepatic function. Treatment continues as long as disease responds (tumors shrinking or stable) and toxicity remains manageable. Many patients experience durable benefit extending beyond 12 months, with some continuing T-DXd for 2+ years before disease progression. Duration of benefit depends on individual biology, metastatic burden, and treatment response—discussing expected timeline with your oncology team helps set realistic expectations for how long T-DXd might sustain disease control.
Treatment Setting and Disease Progression
Previously Treated Patients (DESTINY-Breast04 Evidence)
The DESTINY-Breast04 trial enrolled 336 patients with unresectable or metastatic HER2-low breast cancer who had received at least one prior chemotherapy line, establishing the evidence foundation for T-DXd's current standard approval. These previously treated patients had exhausted one chemotherapy regimen (or experienced early recurrence within 6 months of adjuvant chemotherapy) before receiving T-DXd. The trial demonstrated progression-free survival of 10.1 months with T-DXd versus 5.4 months with standard chemotherapy (typically single-agent taxane), representing 85% improvement in disease control. For hormone receptor-positive patients (the majority of HER2-low cases), progression-free survival extended beyond 12 months, with some patients experiencing exceptional responses lasting multiple years.
The prior treatment requirement reflects the trial design and regulatory approval pathway. Patients entering DESTINY-Breast04 had already received one chemotherapy regimen, establishing that T-DXd's benefit was confirmed in previously treated populations before expanded access was considered. For hormone receptor-positive disease, prior endocrine therapy (at minimum one line) is also expected before T-DXd initiation, as the trial design typically included such therapy. These prior treatment requirements ensure T-DXd is used in appropriate populations where benefit was demonstrated, avoiding potential overtreatment of early-stage disease where long-term safety is unproven.
Chemotherapy-Naive Patients (NEW DESTINY-Breast06 Evidence 2025)
The DESTINY-Breast06 trial represents a paradigm shift by demonstrating T-DXd benefit in chemotherapy-naive patients with hormone receptor-positive, metastatic HER2-low breast cancer. These patients had received prior endocrine therapy establishing hormone receptor dependence but had not received any chemotherapy, potentially offering better quality of life by deferring standard chemotherapy toxicity. The 2025 data from DESTINY-Breast06 showed progression-free survival improvements over standard chemotherapy, establishing T-DXd as potentially first-line chemotherapy in this specific population. However, chemotherapy-naive eligibility applies only to HR-positive metastatic disease—HR-negative HER2-low patients, regardless of metastatic status, must still have received prior chemotherapy before T-DXd eligibility.
This distinction creates separate eligibility pathways: previously treated patients (any HR status, any stage beyond early) requiring ≥1 prior chemo line, versus chemotherapy-naive patients (HR-positive metastatic only) requiring ≥1 prior endocrine therapy but no prior chemo. Patients should confirm which pathway applies to their specific disease characteristics with their oncology team, as this determines eligibility timing and treatment sequencing. The chemotherapy-naive pathway may expand over time to additional populations if ongoing trials demonstrate benefit.
Managing Disease Progression on T-DXd
Progressive disease on T-DXd (tumors growing despite treatment) necessitates discussion of subsequent treatment options. Some patients continue T-DXd despite mild progression if tolerating treatment well, while others pursue alternative approaches immediately upon progression confirmation. Options beyond T-DXd include clinical trials testing novel agents or combinations in HER2-low disease, alternative chemotherapy regimens, or for HR-positive disease, additional endocrine-based combinations. Many academic medical centers and comprehensive cancer centers maintain active HER2-low or breast cancer clinical trials that may provide additional therapeutic options beyond standard approved approaches.
Seeking second opinions at specialized breast cancer centers with extensive T-DXd experience is reasonable when disease progresses, as expert centers may identify clinical trials or treatment approaches not available locally. Some patients benefit from switching to oncologists with particular expertise in HER2-low disease or metastatic breast cancer. The goal of discussing progression openly with your medical team is identifying the next best treatment approach to extend survival while maintaining quality of life.
Alternatives and Special Circumstances
Patients Not Meeting Standard Eligibility
Some patients with HER2-low breast cancer do not meet standard T-DXd eligibility criteria but may have treatment alternatives. Early-stage HER2-low disease, while not approved for T-DXd, may be candidates for ongoing clinical trials testing T-DXd in adjuvant (post-surgical) settings. Patients with HER2-low disease but insufficient prior chemotherapy (less than one line in metastatic setting, or recurrence >6 months after adjuvant chemo) may potentially access T-DXd through clinical trials specifically designed for earlier treatment lines. Insurance appeals occasionally succeed for off-label T-DXd use in exceptional circumstances, though this approach requires extensive documentation and oncologist advocacy.
Alternative HER2-targeted therapies exist for some HER2-low patients, including tucatinib (a HER2 tyrosine kinase inhibitor) combined with trastuzumab and capecitabine for HER2-positive disease, though efficacy specifically in HER2-low patients remains limited compared to T-DXd. Standard chemotherapy regimens remain appropriate for HER2-low patients not eligible or not responding to T-DXd. The key is individualizing treatment selection based on complete disease characteristics, performance status, prior treatment history, and access to clinical trials or experimental approaches that might expand therapeutic options.
Brain Metastases: DEBBRAH Trial Data (NEW 2024)
The DEBBRAH trial, with 2024 data recently presented, provides important information about T-DXd use in patients with brain metastases—one of the most challenging metastatic sites for systemic therapy. This trial evaluated previously treated HER2-low or HER2-ultralow patients with stable brain metastases (not requiring urgent surgery or whole-brain radiation), demonstrating that T-DXd can be used in this population with careful clinical monitoring. Central nervous system (CNS) penetration of T-DXd, though limited compared to some systemic chemotherapy agents, appears sufficient for disease control in selected brain metastasis patients.
Brain metastases considerably complicate treatment planning and prognosis, as many chemotherapy agents poorly penetrate the blood-brain barrier. The DEBBRAH trial data suggesting T-DXd feasibility in stable brain metastases expands treatment options for patients previously thought ineligible for HER2-targeted approaches due to CNS involvement. However, timing of T-DXd initiation relative to neurosurgery or radiation therapy should be individualized based on specific clinical circumstances. Patients with untreated, symptomatic, or rapidly progressive brain metastases may require immediate radiation or surgical intervention before T-DXd initiation. Discussing brain metastases-specific considerations with your medical oncology and neuro-oncology teams ensures integrated treatment planning.
Recurrent HER2 Discordance (Primary vs Metastatic)
HER2 discordance between primary tumor and metastatic sites occurs in approximately 10-20% of breast cancer cases, where HER2 status differs between the original breast cancer and sites of metastatic spread. A patient might have had HER2-negative primary cancer but develop HER2-low or even HER2-positive metastatic disease, or vice versa. This discordance reflects tumor heterogeneity and evolution—different cancer cell populations at different anatomic sites may have divergent HER2 expression. For T-DXd eligibility purposes, HER2 status of metastatic disease takes priority over historical primary tumor testing, as contemporary metastatic biopsy better reflects current tumor biology.
When HER2 status appears to have changed from initial diagnosis, discussion with your pathologist and oncologist should clarify whether the change represents true biologic evolution or potential testing differences. If initial testing was performed before 2023 HER2-low guideline updates, "re-emergence" of HER2-low status might reflect improved detection methods rather than true change. Conversely, documented HER2 status change genuinely suggests tumor biology evolution, potentially affecting prognosis and treatment selection. The practical implication: if you're HER2-negative at initial diagnosis but subsequently found to be HER2-low on metastatic biopsy, you suddenly become eligible for T-DXd—an important conversation to have with your oncology team.
Medical Team Collaboration and Shared Decision-Making
Building Your Healthcare Team
T-DXd eligibility assessment and treatment requires coordinated effort across medical specialists. Your medical oncologist serves as the primary coordinator, responsible for determining T-DXd eligibility, ordering baseline cardiac/pulmonary assessments, managing ongoing treatment, and monitoring for adverse effects. The pathologist plays a critical supporting role, performing HER2 testing and providing expert interpretation of IHC/ISH results—engaging pathologist communication ensures accurate HER2 classification. If available, a genetic counselor can provide context about hereditary cancer risk, particularly important if BRCA mutations are present (which might indicate triple-negative breast cancer biology despite HER2-low status in some cases). Genetic counselors also facilitate communication between different specialists and help patients understand complex genomic information.
Additional team members may include cardiologists or interventional cardiologists if significant cardiac toxicity develops during T-DXd, pulmonologists if ILD symptoms emerge, and radiation oncologists if brain or bone metastases require local therapy. Survivorship specialists help manage long-term treatment effects and quality of life during and after T-DXd therapy. Second opinions at comprehensive cancer centers often involve tumor boards (multidisciplinary team meetings) where various specialists review cases collaboratively, sometimes identifying treatment nuances missed in community practice settings. Building a knowledgeable, communicative healthcare team maximizes the likelihood of optimal T-DXd outcomes.
Resources for Additional Support
Numerous resources exist to help patients navigate T-DXd eligibility, treatment planning, and ongoing support. Patient advocacy organizations such as the American Cancer Society, National Breast Cancer Foundation, and disease-specific groups maintain educational materials and patient support communities. Financial assistance programs including the Enhertu (trastuzumab deruxtecan) patient support program offer potential copay assistance or free medication access for qualified uninsured/underinsured patients. Many cancer centers operate financial counseling services helping patients navigate insurance approval processes and identify funding resources.
Clinical trial finders including clinicaltrials.gov and institutional trial databases help identify ongoing HER2-low research studies that might provide additional treatment options or earlier access to emerging therapies. Genetic counseling resources connect patients with certified genetic counselors, particularly valuable if hereditary cancer syndromes might be relevant. Peer support groups—both in-person and online through organizations like Metastatic Breast Cancer Alliance—connect patients with others navigating similar treatments, providing invaluable emotional support and practical insights. Discussing these resources with your medical team identifies those most relevant to your individual circumstances.
<!-- IMAGE: HER2 Expression Classification System showing IHC 0 (negative) vs IHC 1+ (low) vs IHC 2+ (low/intermediate) vs IHC 3+ (high), with ISH-positive and ISH-negative pathways, and T-DXd eligibility zones marked in color. | Alt: HER2 expression classification by IHC and ISH testing showing eligibility zones for trastuzumab deruxtecan in HER2-low breast cancer --> <!-- IMAGE: T-DXd Eligibility Flowchart showing decision tree with steps: HER2 testing (IHC score?), ISH reflexing (if IHC 2+), metastatic/unresectable status check, prior treatment requirements (chemotherapy? endocrine?), and final eligibility decision (YES/NO). | Alt: Decision tree for trastuzumab deruxtecan eligibility assessment in HER2-low breast cancer including testing requirements and prior treatment criteria -->| HER2 Expression | IHC Score | ISH Result | T-DXd Eligible? | Notes |
|---|---|---|---|---|
| HER2-Positive | 3+ | Any | ❌ No | Use standard trastuzumab, pertuzumab |
| HER2-Intermediate-High | 2+ | Positive | ❌ No | Use standard HER2-directed therapy |
| HER2-Low | 2+ | Negative | âś… YES | Gold standard for T-DXd |
| HER2-Low | 1+ | Not required | âś… YES | T-DXd eligible |
| HER2-Ultralow (NEW) | 0 | Minimal expression | âś… YES (2025+) | New FDA approval category |
| HER2-Negative | 0 | Negative | ❌ No | Standard chemotherapy |
Table 1 Caption: HER2 expression testing interpretation matrix showing trastuzumab deruxtecan eligibility by IHC score and ISH status in breast cancer
| Criteria | Previously Treated (DESTINY-Breast04) | Chemotherapy-Naive (DESTINY-Breast06 — 2025) |
|---|---|---|
| HER2 Status | IHC 1+ or IHC 2+/ISH negative | IHC 1+, IHC 2+/ISH negative, or IHC 0 with minimal expression |
| Disease Status | Unresectable/metastatic | Metastatic HR+ only |
| Prior Chemotherapy | ≥1 line for metastatic OR recurrence within 6mo after adjuvant | None (chemotherapy-naive) |
| Prior Endocrine (HR+) | Required | ≥1 line (CDK4/6i, AI, tamoxifen, fulvestrant) |
| Brain Metastases | Allowed if treated/stable (DEBBRAH data) | Status unclear in trials |
| LVEF Baseline | Required (echo/MUGA) | Required |
Table 2 Caption: Trastuzumab deruxtecan eligibility criteria comparison between previously treated and chemotherapy-naive HER2-low breast cancer populations
| Parameter | Baseline | During Treatment | Frequency | Action if Abnormal |
|---|---|---|---|---|
| LVEF | Echo/MUGA | Echo/MUGA | 1mo, then Q3mo | Hold if >10% drop or <LLN |
| CBC | Yes | Yes | Before each dose | Dose delay if neutropenia |
| Chest Imaging | CXR or CT | CT | Q6-9 weeks | Evaluate for ILD if symptoms |
| Symptoms Assessment | History | At each visit | Weekly (patient self-report) | Urgent CT if respiratory symptoms |
| Disease Assessment | Imaging baseline | RECIST imaging | Q6-9 weeks | Discuss progression if present |
| Dose | N/A | 5.4 mg/kg IV | Every 3 weeks | Reduce to 4.4 mg/kg or 3.2 mg/kg if toxicity |
Table 3 Caption: Trastuzumab deruxtecan monitoring schedule and parameters during treatment for HER2-low breast cancer
FAQ
Q: What exactly is HER2-low breast cancer and how is it different from HER2-negative?
HER2-low breast cancer, defined as IHC 1+ or IHC 2+/ISH-negative, represents a distinct category historically grouped with HER2-negative disease. The fundamental difference lies in biological behavior—HER2-low tumors express modest amounts of HER2 protein on cancer cell surfaces, while true HER2-negative (IHC 0) tumors express no detectable HER2. This seemingly small biological difference has profound therapeutic implications: HER2-low tumors respond to trastuzumab deruxtecan, while HER2-negative tumors do not. Prior to the 2023 CAP/ASCO guideline updates, pathology reports classified both HER2-low and HER2-negative as simply "HER2-negative," preventing patients from accessing T-DXd. Today's precise HER2 classification system distinguishes these populations, allowing appropriate therapy matching. Approximately 50-70% of tumors previously reported as HER2-negative actually qualify as HER2-low, explaining why reassessing archival pathology is increasingly important for treatment planning.
Q: How accurate is HER2-low testing and what is inter-observer concordance?
HER2 IHC testing demonstrates 73-95% inter-observer concordance, with greatest variability when distinguishing IHC 0 from IHC 1+ (where HER2-low definition begins). Testing accuracy improves significantly with experienced pathologists trained in HER2-low interpretation, validated antibody clones (4B5 and SP3 showing highest concordance), and proper tissue fixation (6-72 hours optimal). Many laboratories participate in CAP proficiency testing programs validating their HER2 measurement accuracy through external quality assessments. If diagnostic uncertainty exists regarding HER2-low status, particularly if testing predates 2023 guideline updates, requesting pathology re-review by expert pathologists or repeat biopsy with contemporary testing protocols can provide reassurance and definitively establish classification. International quality standards and interlaboratory comparisons continue improving HER2-low testing reliability across institutions.
Q: Can I qualify for trastuzumab deruxtecan with only one prior chemotherapy line?
Yes, T-DXd eligibility requires exactly one prior chemotherapy line for metastatic disease or disease recurrence within 6 months of completing adjuvant chemotherapy—not multiple lines. The DESTINY-Breast04 trial established efficacy in this population, enrolling patients who had received only 1-2 prior chemotherapy lines. For hormone receptor-positive disease, you also need prior endocrine therapy (at minimum one line such as CDK4/6 inhibitor with aromatase inhibitor, or single-agent hormone therapy). This one-line requirement means patients can access T-DXd relatively early in their metastatic cancer journey, potentially before multiple chemotherapy regimens are exhausted. The chemotherapy-naive pathway (DESTINY-Breast06) allows T-DXd even earlier for HR-positive patients, requiring only prior endocrine therapy without any prior chemotherapy.
Q: Does HER2 status change over time and should I get re-tested?
HER2 expression can genuinely evolve between initial diagnosis and metastatic recurrence, with documented discordance rates of 10-20% between primary and metastatic sites. This variation reflects tumor heterogeneity—different cancer cell populations at different anatomic locations may have divergent HER2 expression. Current guidelines recommend HER2 testing on the most recent available biopsy, particularly metastatic tissue, as this reflects current tumor biology affecting treatment planning. If your last HER2 test was performed on primary tumor tissue obtained 2-5 years ago, discussion with your oncologist about repeat testing of metastatic disease is appropriate. Tumor heterogeneity considerations also apply within single tumors, where some cancer cells may express HER2 while others do not, explaining why multiple sampling sometimes reveals discordant results.
Q: What happens if I'm HER2-ultralow instead of HER2-low?
HER2-ultralow (IHC 0 with minimal detectable membrane expression) represents the newly approved 2025 FDA category expanding T-DXd eligibility beyond traditional HER2-low criteria. Data from DESTINY-Breast05 and confirmatory DESTINY-Breast06 trial results demonstrated clinical benefit of T-DXd in ultralow patients, establishing the biological rationale for including this population. HER2-ultralow eligibility applies specifically when IHC scoring is 0 (completely negative for HER2) but specialized pathology assessment detects minimal membrane staining activity just above the negativity threshold. This distinction is important because not all IHC 0 cases qualify as ultralow—true IHC 0 with no membrane expression remains HER2-negative ineligible for T-DXd. Pathologists must specifically document whether IHC 0 cases show minimal membrane expression to qualify for ultralow category. If you have IHC 0 results, ask your pathologist or oncologist whether ultralow classification applies to your specific case.
Q: What is the success rate of trastuzumab deruxtecan for HER2-low patients?
T-DXd demonstrates remarkable efficacy in HER2-low breast cancer compared to standard chemotherapy. The DESTINY-Breast04 trial showed objective response rate (tumor shrinkage) of 62% with T-DXd versus 34% with chemotherapy alone—meaning nearly 2 in 3 patients achieved measurable tumor response to T-DXd. More importantly for survival, progression-free survival reached 10.1 months with T-DXd versus 5.4 months with chemotherapy, representing 85% improvement in disease control duration. For hormone receptor-positive patients (the majority of HER2-low cases), progression-free survival often exceeded 12 months, with some patients experiencing exceptional durability lasting 2+ years. Complete response (complete tumor disappearance) occurs in approximately 5-10% of patients. Individual outcomes vary significantly based on hormone receptor status, disease burden, performance status, and other factors, making it important to discuss expected benefit and timeline with your specific oncology team.
Q: What are the side effects I should monitor on T-DXd and how serious is ILD?
T-DXd's most common side effects include fatigue, nausea, decreased blood counts (neutropenia, anemia, thrombocytopenia), and diarrhea. More serious adverse effects include cardiotoxicity (LVEF decline) affecting about 10-15% of patients, and interstitial lung disease affecting approximately 12% with 0.8% fatality rate. ILD represents the most serious concern, characterized by new cough, shortness of breath, fever, or chest discomfort indicating lung inflammation/scarring. ILD typically develops within the first 3-6 months of T-DXd treatment. Grade 2 or higher ILD mandates permanent treatment discontinuation, as continuing risks life-threatening ILD progression. However, early detection through prompt reporting of respiratory symptoms and immediate evaluation dramatically improves outcomes. Baseline chest imaging and vigilant self-monitoring for ILD symptoms allow early intervention. Grade 1 ILD (asymptomatic radiologic findings) may allow continued treatment with intensive monitoring. Discussing ILD surveillance protocols and symptom awareness with your medical team provides actionable plans for safe T-DXd administration.
Q: How long can I stay on trastuzumab deruxtecan if it's working?
Treatment duration varies individually based on disease response and toxicity tolerance. Many patients continue T-DXd for 12-24+ months if experiencing disease control (tumors shrinking or stable) and manageable side effects. Response assessment imaging (typically CT or PET scans) every 6-9 weeks determines if tumors are responding, progressing, or stable. As long as disease remains stable or shrinking and T-DXd toxicity remains manageable through dose modifications if needed, treatment typically continues. Some patients tolerate T-DXd remarkably well for years; others require dose reductions (to 4.4 mg/kg or 3.2 mg/kg) or temporary discontinuations managing toxicity. The goal remains balancing disease control against treatment side effects, maintaining quality of life while extending survival. Discussing expected treatment duration and reassessing goals regularly with your medical team ensures optimal balance between benefit and burden.
Q: What should I do if I don't meet all T-DXd eligibility criteria?
Several alternatives exist for patients not meeting standard T-DXd eligibility. Clinical trials represent the most promising avenue, with many centers conducting studies testing T-DXd in earlier treatment lines (for patients with insufficient prior chemotherapy), early-stage disease (adjuvant settings), or special populations like brain metastases or HER2-ultralow disease. Clinical trial information can be found through clinicaltrials.gov or your institution's research department. Off-label use occasionally succeeds through insurance appeals when clinical circumstances support T-DXd benefit despite not meeting standard criteria, though this requires extensive documentation and oncologist advocacy. Alternative HER2-targeted therapies including tucatinib-based combinations may apply for HER2-positive disease or certain HER2-low cases. Standard chemotherapy regimens remain appropriate and effective for patients not eligible for T-DXd. Discussing all available options, including clinical trial access, with your medical oncology team ensures comprehensive treatment planning.
Q: How does T-DXd compare to other HER2-targeted therapies?
T-DXd represents a fundamentally different approach compared to traditional HER2-targeted therapies like trastuzumab and pertuzumab used for HER2-positive disease. Traditional HER2-targeted antibodies (trastuzumab, pertuzumab) bind HER2 and block its function, requiring high HER2 expression to work effectively. T-DXd is an antibody-drug conjugate—trastuzumab linked to deruxtecan (topoisomerase I inhibitor chemotherapy)—that delivers direct cytotoxic payload into HER2-expressing cells, working even at low HER2 expression levels. This mechanistic difference explains why T-DXd succeeds in HER2-low disease where traditional antibody-based therapy does not. For HER2-positive patients, traditional trastuzumab/pertuzumab combinations typically remain first-line given extensive historical evidence. T-DXd increasingly plays roles in HER2-positive disease after progression on traditional therapies. Comparing specific therapies for your individual disease characteristics requires discussion with your medical oncology team based on your complete clinical picture.
Q: Are there clinical trials testing T-DXd in earlier treatment settings?
Yes, multiple ongoing clinical trials explore T-DXd in earlier disease settings or special populations. DESTINY-Breast06 (now enrolling/completed) tests chemotherapy-naive populations, potentially establishing T-DXd as first-line chemotherapy for HR-positive metastatic HER2-low patients. DESTINY-Breast05 explores HER2-ultralow populations. Earlier-stage adjuvant (post-surgical) trials are actively recruiting, testing whether T-DXd improves recurrence-free survival in HER2-low early-stage disease. Combination trials pair T-DXd with endocrine therapy, immunotherapy, or other targeted agents attempting to enhance benefit. Clinical trial availability varies by institution, with comprehensive cancer centers typically offering more options than community practices. Asking your medical oncology team about available trials specific to your disease stage and characteristics is essential, as clinical trial access might provide therapeutic options otherwise unavailable.
Q: What resources are available to help with T-DXd costs and insurance coverage?
T-DXd (brand name Enhertu) carries significant cost, typically exceeding $10,000-$15,000 per infusion. Multiple resources exist to reduce financial burden. The manufacturer's patient assistance program (Enhertu Patient Support Program through Daiichi Sankyo) offers copay assistance or free medication access for qualified uninsured or underinsured patients meeting income criteria. Many cancer centers operate financial counseling departments helping navigate insurance approval processes, identify government assistance programs (Medicaid, Medicare Extra Help), and connect patients with nonprofit cancer assistance organizations. Organizations like American Cancer Society, National Breast Cancer Foundation, and CancerCare offer treatment-specific financial assistance and grant programs. Discussing financial concerns openly with your medical team and cancer center financial counselor ensures you're aware of all potential assistance, preventing financial barriers from limiting access to potentially beneficial therapy.
Conclusion
Understanding your eligibility for HER2-low trastuzumab deruxtecan eligibility requires careful attention to your HER2 testing results, disease status, and prior treatment history. Your specific IHC score—whether 1+, 2+ with negative ISH, or the newly approved ultralow category (IHC 0 with minimal expression)—determines whether T-DXd therapy applies to your individual case. Gathering complete pathology documentation, treatment history, and recent imaging creates the foundation for productive eligibility assessment discussions with your oncology team. If you were diagnosed with HER2-negative breast cancer before 2023, requesting contemporary HER2 re-review with updated classification protocols might reveal HER2-low status previously undetected, opening access to this potentially transformative therapy.
The clinical evidence from DESTINY-Breast04 and DESTINY-Breast06 trials demonstrates remarkable T-DXd efficacy—progression-free survival improvements of 85% compared to standard chemotherapy and potential 2+ year disease control duration for responsive patients. This represents substantial potential benefit for qualified HER2-low patients, particularly those with hormone receptor-positive disease experiencing earlier therapeutic access through the chemotherapy-naive pathway. Your medical oncology team remains your best resource for determining individual eligibility, planning baseline cardiac and pulmonary assessments, and initiating treatment if you qualify.
Engage with your healthcare team collaboratively, bringing organized medical documentation, asking specific questions about your HER2 classification and T-DXd eligibility, and discussing all treatment alternatives including clinical trials. Building a knowledgeable, communicative team across medical oncology, pathology, and supportive care specialists maximizes the likelihood of optimal outcomes. Remember that HER2-low trastuzumab deruxtecan eligibility continues evolving—newer trials expand access to earlier treatment lines, special populations, and combination approaches, so remaining engaged with emerging treatment options remains important throughout your cancer journey.
đź“‹ Educational Content Disclaimer
This article provides educational information about genetic variants and is not intended as medical advice. Always consult qualified healthcare providers for personalized medical guidance. Genetic information should be interpreted alongside medical history and professional assessment.